- Home
- INSM vs GRMN Comparison
INSM vs GRMN Comparison
Compare INSM & GRMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- GRMN
- Stock Information
- Founded
- INSM 1988
- GRMN 1990
- Country
- INSM United States
- GRMN Switzerland
- Employees
- INSM N/A
- GRMN N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- GRMN Industrial Machinery/Components
- Sector
- INSM Health Care
- GRMN Industrials
- Exchange
- INSM Nasdaq
- GRMN Nasdaq
- Market Cap
- INSM 41.2B
- GRMN 40.5B
- IPO Year
- INSM 2000
- GRMN 2000
- Fundamental
- Price
- INSM $206.24
- GRMN $194.91
- Analyst Decision
- INSM Strong Buy
- GRMN Hold
- Analyst Count
- INSM 19
- GRMN 4
- Target Price
- INSM $173.35
- GRMN $239.50
- AVG Volume (30 Days)
- INSM 3.0M
- GRMN 1.2M
- Earning Date
- INSM 10-30-2025
- GRMN 10-29-2025
- Dividend Yield
- INSM N/A
- GRMN 1.85%
- EPS Growth
- INSM N/A
- GRMN 3.11
- EPS
- INSM N/A
- GRMN 8.11
- Revenue
- INSM $447,022,000.00
- GRMN $6,943,125,000.00
- Revenue This Year
- INSM $40.09
- GRMN $15.45
- Revenue Next Year
- INSM $129.64
- GRMN $6.78
- P/E Ratio
- INSM N/A
- GRMN $24.03
- Revenue Growth
- INSM 30.34
- GRMN 16.56
- 52 Week Low
- INSM $60.40
- GRMN $169.26
- 52 Week High
- INSM $209.77
- GRMN $261.69
- Technical
- Relative Strength Index (RSI)
- INSM 70.57
- GRMN 31.04
- Support Level
- INSM $194.65
- GRMN $186.67
- Resistance Level
- INSM $209.77
- GRMN $194.27
- Average True Range (ATR)
- INSM 6.85
- GRMN 4.22
- MACD
- INSM 0.15
- GRMN 1.10
- Stochastic Oscillator
- INSM 86.77
- GRMN 46.71
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About GRMN Garmin Ltd. (Switzerland)
Garmin produces GPS-enabled hardware and software for five sectors: fitness, outdoors, automotive, aviation, and marine. Garmin has built a strong reputation for durable, high-precision devices through a vertically integrated design and manufacturing approach. The company's product lines include smartwatches, fitness trackers, communication equipment, and a comprehensive suite of systems for marine and aviation navigation. Garmin operates globally, with its business focused primarily on North America and Europe.